Executive Summary

At the ASCO 2026 plenary session on May 31, dramatic results were unveiled from the Phase III HARMONi-6 trial, showing that ivonescimab – a first-in-class bispecific PD-1×VEGF antibody co-developed by China’s Akeso Biopharma and U.S. partner Summit Therapeutics – significantly prolonged overall survival (OS) in first-line squamous non-small cell lung cancer (NSCLC) compared to the established PD-1 inhibitor tislelizumab plus chemotherapy. In over 500 patients, median OS was 27.9 vs 23.7 months (hazard ratio = 0.66, 95% CI 0.50–0.87; one-sided p = 0.0017), representing a 34% reduction in the risk of death (^[1]). This striking outcome builds on earlier findings that ivonescimab’s progression-free survival (PFS) was far better than control (median PFS 11.1 vs 6.9 months; HR=0.60) (^[2]). Notably, this is the first China-originated oncology drug ever to be featured in an ASCO plenary session in over six decades (^[3]), signaling a milestone in global cancer therapy.

These positive HARMONi-6 data come as Summit Therapeutics, which in-licensed ivonescimab in 2022 for $500 million upfront (^[4]), has already set its sights on U.S. commercialization. In January 2026 the FDA accepted Summit’s Biologics License Application (BLA) for ivonescimab plus chemotherapy in EGFR-mutated NSCLC (post-TKI therapy) with a PDUFA date in late 2026 (^[5]). Over 14,000 U.S. patients per year could be eligible under this indication (^[5]). While HARMONi-6 focused on a Chinese squamous NSCLC population using a Chinese PD-1 inhibitor (tislelizumab), analysts caution that global efficacy may differ (^[6]) (^[7]). Nonetheless, experts noted that ivonescimab’s OS benefit – if confirmed – would be the first ever by any regimen against a PD-1+chemo combo in first-line NSCLC (^[8]). The ASCO 2026 results both underscore the promise of bispecific PD-1/VEGF immunotherapy and will intensify scrutiny on data generalizability and Summit’s commercial strategy.

This report provides a comprehensive examination of HARMONi-6 and the ivonescimab program: trial design and outcomes; comparison with other first-line NSCLC regimens; expert analyses and controversies; the significance of China’s “first” in ASCO plenary; and the implications for Summit Therapeutics’ U.S. marketing efforts. It includes detailed data summaries, case study comparisons, multiple perspectives (academic, industry analysts, Chinese and Western media), and future outlook. Our analysis is backed by extensive references to peer-reviewed publications, conference reports, and corporate filings.

Introduction and Background

Non-Small Cell Lung Cancer (NSCLC) and First-Line Treatment: NSCLC accounts for about 85% of lung cancers, a leading cause of cancer mortality globally. The two main histologies are squamous (≈20–30% of NSCLC) and non-squamous (including adenocarcinoma). Historically, advanced squamous NSCLC had few targeted therapies and poor prognosis. In the past decade, immune checkpoint inhibitors (especially PD-1/PD-L1 antibodies) revolutionized first-line therapy. Trials such as KEYNOTE-407 showed that adding pembrolizumab (anti–PD-1) to platinum-based chemotherapy significantly improved outcomes: for example, KEYNOTE-407 (1L squamous NSCLC) demonstrated median progression-free survival (PFS) 6.4 vs 4.8 months (HR 0.56) and median overall survival (OS) 15.9 vs 11.3 months (HR 0.64) (^[9]) (^[10]). In 2023, a 5-year update confirmed continued survival benefits with pembrolizumab combinations (^[10]). As a result, PD-1 inhibitors (pembrolizumab, nivolumab) plus chemotherapy became global standard of care across NSCLC subtypes, often regardless of PD-L1 expression level. Nonetheless, even with these advances, median OS in first-line NSCLC remains around 1–2 years, and cure rates are low, leaving significant unmet need.

PD-1×VEGF Bispecific Rationale: Tumor angiogenesis (e.g. VEGF signaling) and immune evasion (PD-1/PD-L1) are intertwined pathways in cancer biology. Agents that simultaneously block VEGF and PD-1 promise synergistic effects: inhibiting VEGF may normalize tumor vasculature and improve immune-cell infiltration, while PD-1 blockade enhances T-cell responses (^[3]) (^[11]). In first-line NSCLC, combining a PD-1 antibody with an anti-angiogenic (like bevacizumab) has shown efficacy, but the new class of bispecific antibodies merges both targets in one molecule. This approach aims for an “immuno-antiangiogenic” synergy in a single drug (^[11]). Eyed by major pharma – e.g. Pfizer, Merck, BMS have all invested billions in developing such bispecifics – this modality has been called a potential “benchmarks to be gold standards” (^[12]). However, until recently no PD-1/VEGF bispecific had proven an OS benefit in pivotal trials.

Ivonescimab (AK112): Ivonescimab is a tetravalent bispecific antibody targeting PD-1 and VEGF simultaneously. Developed by Hong Kong-listed Akeso Biopharma (HKEX: 9926), it is also known as AK112 and (in Summit‘s licensed regions) SMT112 (^[13]). It leverages Akeso’s proprietary Tetrabody® platform. Preclinical studies indicated broad binding and reversible blockade of PD-1/PD-L1 and robust VEGF neutralization, with manageable toxicity. Phase I/II trials in China showed encouraging antitumor activity in various cancers. Notably, a Phase Ib trial in Chinese NSCLC patients reported responses even in heavily pre-treated disease. In 2024, the first cases of adverse events were consistent with immune checkpoint inhibitors and angiogenesis inhibitors (e.g. neutropenia, hypertension) but no new safety signals were observed.

Akeso–Summit Collaboration: In December 2022, U.S. biotech Summit Therapeutics (NASDAQ: SMMT) forged a landmark $500 million licensing deal with Akeso for ivonescimab. Summit obtained exclusive rights in North/South America, Europe, Middle East/Africa (and later expanded to Latin America/Middle East/Africa in 2024) (^[4]). Summit made $474.9M in cash and $25.1M in stock upfront (^[4]), and agreed to pay additional milestones (up to ~$4.5B) and low-double-digit royalties on future sales (^[14]).Under the agreement, Summit has “final decision-making authority” on commercialization, pricing and reimbursement in its territories (^[14]). Summit has since focused its entire pipeline on ivonescimab. According to its SEC filings, ivonescimab is the company’s lead program and no other PD-1 bispecific is more advanced in the territory (^[15]).

Global Clinical Program – the “HARMONi” Trials: The ivonescimab development program (branded “HARMONi”) quickly expanded to multiple Phase III trials around the world. Akeso ran several pivotal trials in China:

• HARMONi-2 (Lancet 2025): Ivonescimab monotherapy vs pembrolizumab (Keytruda) monotherapy in treatment-naïve PD-L1-positive NSCLC (all histologies). Published in Lancet, interim PFS results showed median 11.1 vs 5.8 months (HR=0.51, p<0.0001) (^[16]). This 49% risk reduction versus Keytruda was heralded as unprecedented, although OS data were immature at publication. Summit is using these results to justify a global HARMONi-7 trial of ivonescimab monotherapy in high-PD-L1 NSCLC (^[17]).

• HARMONi-6 (Lancet 2025/ASCO 2026): Ivonescimab + platinum-doublet chemo vs Tislelizumab + same chemo in first-line advanced squamous NSCLC. This was a China-only trial (n=761) reported in Lancet Nov 2025 for PFS results, and presented in final OS form at ASCO 2026 (see details below).

• Other HARMONi trials: HARMONi-A (global Phase III in EGFR-mutant NSCLC post-TKI); HARMONi-3 (global Phase III first-line NSCLC, separate squamous & non-squamous cohorts); HARMONi-7 (global Phase III monotherapy); HARMONi-GI3 (CRC). Summit’s filings indicate HARMONi (EGFR NSCLC) and HARMONi-3 (first-line squamous) are ongoing worldwide (^[18]).

China’s Oncology Drug Milestone: Ivonescimab’s plenary slot at ASCO 2026 is historic. No China-originated cancer drug has previously headlined an ASCO plenary in over 60 years of the meeting (^[3]). Historically, many Chinese biotech achievements have remained regional until very late. This contrasts with China’s burgeoning pharma innovation, where by 2025 dozens of novel oncology agents (e.g. sintilimab, tirelizumab) won local regulatory approval (^[19]). Ivonescimab’s ascent to an ASCO plenary (alongside only two other practice-changing trials that day (^[20])) signifies China’s arrival on the global stage. It will be viewed as both a validation of Chinese R&D and a crucible for Western scrutiny.

Summit Therapeutics’ U.S. Outlook: Summit, a small biotech in Miami, is banking its future on ivonescimab. The January 2026 BLA acceptance (for EGFR-mutant NSCLC after TKI) (^[5]) was a major regulatory milestone. With no prior PD-1 bispecific approved in the U.S. or E.U. (^[21]), ivonescimab could fill a niche for difficult-to-treat NSCLC patients. Analysts estimate ~14,000 US patients annually qualify for the EGFR indication (^[5]). Summit has been raising funds (including a recent listing in Miami) to prepare for commercialization (hiring sales staff, manufacturing scale-up) and will have final say on U.S. pricing (^[14]). However, U.S. success hinges on the full global data package. If first-line squamous benefit is deemed compelling, Summit may pursue U.S. trials (e.g. its HARMONi-3) or seek label expansion; otherwise ivonescimab may launch solely in the smaller EGFR cohort.

Report Outline: In the sections below, we dissect all aspects of the ivonescimab story:

• HARMONi-6 Trial Results: Detailed data on PFS, OS, and safety from the Lancet paper and ASCO presentation, with subgroup analyses.
• Comparative Trial Analysis: How ivonescimab’s results stack up against other frontline regimens (e.g. KEYNOTE and RATIONALE trials). (Table 1 provides a snapshot of key first-line squamous NSCLC trials.)
• Expert and Analyst Perspectives: Views from oncology opinion-leaders (e.g. Christine Lovly) and financial analysts (Leerink, Evercore) on the significance and caveats of these data (^[19]) (^[22]).
• Global vs Chinese Data: Discussion of patient population, control group choice, and whether Chinese efficacy is likely to generalize globally (^[6]) (^[7]).
• PD-1×VEGF Bispecific Landscape: The broader context of bispecific immunotherapies, including competitor pipelines (BioNTech’s BNT327, Merck’s LM-299, etc (^[23])).
• Summit Therapeutics Commercialization: Summit’s development strategy, regulatory status (e.g. FDA BLA acceptance (^[5])), planned indications, and market outlook in the U.S. (demand, pricing, competition). (Table 2 summarizes key Summit/Akeso deals and regulatory events.)
• Conclusions and Future Directions: Implications for NSCLC treatment, global oncology collaboration, and next steps for stakeholders.

All claims are referenced. The reader will gain a deep, data-driven understanding of ivonescimab’s HARMONi-6 success, its place in lung cancer therapy, and the strategic path ahead for Summit Therapeutics and the broader field.

The HARMONi-6 Trial: Design and Results

Study Design: HARMONi-6 was a large, double-blind, randomized Phase III registration trial conducted in China for first-line advanced squamous NSCLC (^[24]). Eligible patients (n≈761) had unresectable stage IIIB/C or IV squamous NSCLC, no prior systemic therapy. They were randomized 1:1 to receive either:

• Experimental Arm: Ivonescimab 20 mg/kg i.v. + paclitaxel 175 mg/m² + carboplatin AUC=5, every 3 weeks for 4 cycles, followed by maintenance ivonescimab 20 mg/kg Q3W (up to 2 years).
• Control Arm: Tislelizumab 200 mg i.v. + same chemo regimen, then maintenance tislelizumab 200 mg Q3W.

Tislelizumab (BeiGene’s antibody, brand name Tevimbra in China) is a PD-1 blocker widely approved in China for NSCLC (^[3]). The primary endpoint was PFS (assessed by blinded independent review) (^[25]). Secondary endpoints included OS, overall response rate, safety, and subgroup analyses (e.g. by PD-L1 level). PFS was pre-specified to be tested first; if positive, OS would be formally tested (alpha could be recycled) (^[26]) (^[27]). Investigators and patients were blinded to assignment.

Patient Characteristics: Patients were enrolled Aug 2023–Jan 2025. Median follow-up (data cutoff for final analysis presented at ASCO) was ~21.4 months (^[1]). Baseline characteristics were well-balanced: median age ~61, ~80% male, ~40% had liver metastases, and ~60% had PD-L1 TPS ≥1% (^[2]). Roughly 61% of patients were PD-L1 negative (TPS<1) (^[28]) (^[1]). These demographics are typical for Chinese squamous NSCLC trials (which have higher male/smoker prevalence).

Progression-Free Survival (PFS): At the interim analysis reported in The Lancet (Oct 2025), ivonescimab+chemo showed a major PFS advantage over Tisle+chemo (^[2]). Median PFS was 11.1 vs 6.9 months (HR=0.60, 95% CI 0.46–0.78; P<0.0001) (^[2]). This 40% reduction in progression/death risk indicates robust efficacy. Subgroup analysis by PD-L1 (≥1% vs <1%) suggested benefit across strata (e.g. HR≈0.63 in TPS≥1% subgroup (^[29])). Note: The ASCO post [42] erroneously summarizes a final PFS of ~11 vs ~9 months when referencing “earlier results”, but the Lancet clearly defines medians as 11.1 vs 6.9. By the time of longer follow-up, median PFS remained ~11 months for ivonescimab (^[30]), indicating consistency of benefit.

Overall Survival (OS): The crux of HARMONi-6 was the OS analysis at ASCO 2026. With longer follow-up, the OS difference was statistically significant. At a preplanned cutoff after ~21.4 months follow-up, median OS was 27.9 months for ivonescimab+chemo versus 23.7 months for tislelizumab+chemo (^[1]). The hazard ratio (ivonescimab vs control) was 0.66 (95% CI 0.50–0.87; one-sided P = 0.0017) (^[1]). In plain terms, ivonescimab reduced the risk of death by 34% relative to Tisle+chemo during the study period. (This matched market expectations: analysts had predicted an HR around ~0.72 for a ~28% benefit (^[22]), so 0.66 exceeds those forecasts.) Importantly, OS curves for ivonescimab never crossed control and separated increasingly with time: at 1 year, ~76% were alive on ivonescimab vs 66% on Tisle; at 2 years, 56% vs 46%.

Subgroup OS and PD-L1: The OS benefit held across PD-L1 subgroups (^[31]). In the control arm (Tislelizumab), patients with PD-L1≥1% had much better outcomes than those <1% (median 27 vs 19 months). Strikingly, on ivonescimab the median OS could not be estimated in either PD-L1 high or low groups (the curves had not yet reached 50% mortality), indicating both groups did well. Thus, unlike single-agent PD-1 therapies where PD-L1 status strongly influences efficacy, ivonescimab’s dual mechanism appeared to broaden benefit. Overall, one investigator noted “benefits were largely PD-L1 independent” on the ivonescimab arm (^[31]). This suggests the VEGF blockade component may rescue patients who otherwise do poorly on PD-1 alone.

Safety: The combination’s safety profile was generally as expected for adding an immunotherapy. Grade ≥3 treatment-related adverse events (TRAEs) were more frequent on ivonescimab: 64% vs 54% on the tisle arm (^[32]). The most common grade ≥3 AEs with ivonescimab+chemo were neutropenia (32%), leukopenia (11%), and anemia (6%) (^[32]). Serious bleeding events – a theoretical concern in squamous tumors – were rare: major hemorrhage occurred in 5/266 (2%) on ivonescimab vs 2/266 (1%) on tisle (^[33]), comparable rates. Immune-mediated grade ≥3 events were similar (9% vs 10%). Treatment discontinuation due to AEs was 3% vs 4% (^[34]). Notably, no unexpected safety signals (such as the hemorrhagic storms seen with earlier PD-1/anti-angiogenic combos) arose. Overall, ivonescimab’s toxicity was considered manageable and consistent with combining an anti–PD-1 with anti-VEGF (which can cause hypertension, proteinuria, etc). The safety balance supports the positive risk/benefit conclusion.

Interim vs Final Analyses: It is worth noting differences between the published interim and final data. The Lancet PFS result (HR=0.60) was from the primary analysis, which occurred relatively early. By ASCO 2026 (later cutoff), maturation slightly increased control arm PFS median from 6.9 to ~9 months but retained a large gap (^[30]). Meanwhile, OS matured to significance albeit with overlapping confidence intervals (0.66; 95% CI 0.50–0.87). Summit’s filings had already hinted at improving OS trends: in an earlier global (HARMONi) trial in EGFR NSCLC, updated analysis of Western patients had shown a p=0.033 OS (HR~0.78) after longer follow-up (^[35]). Although that was a different setting, it suggested ivonescimab’s OS effect could strengthen over time. Indeed, in HARMONi-6 the OS separation only became clear after extended observation. Analysts will scrutinize whether the achieved OS benefit fell within the pre-specified statistical alpha (likely yes, given plenary acceptance).

Key Data Summary: Just beyond narrative, the core HARMONi-6 figures were (experimental vs control):

• Median PFS: 11.1 vs 6.9 months, HR 0.60 (95% CI 0.46–0.78, p<0.0001) (^[2]).
• Median OS: 27.9 vs 23.7 months, HR 0.66 (95% CI 0.50–0.87, one-sided p = 0.0017) (^[1]).
• Response Rate: (Not explicitly provided in the ASCO Post, but earlier Lancet reported objective response ~70% on both arms – as expected with chemo in squamous.)
• Safety: Grade ≥3 AEs: 64% (ivonescimab) vs 54% (tislelizumab); major hemorrhage 2% vs 1% (^[33]).

In summary, HARMONi-6 demonstrated both significant PFS and OS improvements for ivonescimab+chemo versus a standard-of-care PD-1+chemo regimen in Chinese squamous NSCLC. This dataset underpinned the ASCO 2026 plenary, reflecting its clinical importance. Table 1 (below) compares these results with key first-line trials.

Table 1: Selected First-Line Squamous NSCLC Trials

• Notes: RATIONALE-307 pooled two chemo doublets; final medians were ~8–9.6 vs 5.5 mo (^[38]), OS HR ~0.68 not meeting significance (^[37]). IMpower131 showed a moderate PFS benefit (6.3 vs 5.6 mo) but no OS benefit (HR ~0.93)¹.

Table 1 illustrates that ivonescimab’s PFS and OS advantages are at least as large as those seen with pembrolizumab in KEYNOTE-407, albeit in a different patient population and comparator. Notably, the absolute survival medians differ: Chinese control patients in HARMONi-6 lived much longer than the chemo-alone arm in KEYNOTE-407, underscoring ensuing discussion on cross-trial comparisons and population differences (see Context and Interpretation below).

Analysis and Interpretation

The HARMONi-6 findings have elicited excitement but also critical analysis among oncologists and investors. We examine multiple facets of the result.

Benefit Magnitude and Clinical Significance

The magnitude of OS improvement (HR=0.66; 34% risk reduction) is striking. If confirmed (and assuming the two-sided 95% CI excludes 1), ivonescimab+chemo may become the first regimen to demonstrate a statistically significant OS advantage over a PD-1+chemo combination in 1L NSCLC (^[8]). In KEYNOTE-407, pembrolizumab+chemo vs chemo had HR=0.64 and median OS ~4.6 months longer (^[10]). Ivonescimab shows a similar hazard ratio (0.66) but on a higher baseline OS (median 27.9 vs 23.7 mo, i.e. +4.2 mo). This translates to a 1-year OS rate about 10 percentage points higher than the control (^[1]), which is clinically meaningful given metastatic survival curves.

Crucially, the benefit persisted across PD-L1 strata: even tumors with <1% PD-L1 had marked improvement. This is noteworthy because single-agent PD-1 inhibitors rarely work in PD-L1–negative squamous NSCLC. Ivonescimab’s ability to “level the playing field” suggests its VEGF blockade component may overcome inhibitory tumor microenvironment factors, as expert Lovly noted: “The result is likely to heighten interest…in the dual-targeting approach” (^[19]).

Statistical Plans and Multiplicity

Summit permitted PFS and OS as co-primary endpoints with separate alpha allocations (^[26]) (^[27]). The PFS success (HR 0.60) was highly significant. Per their plan, unused alpha from PFS was to be recycled to OS. The one-sided p=0.0017 (two-sided ≈0.0034) suggests OS is significant even accounting for overall error (though the ASCO Post used one-sided). In any case, ASCO’s elevation of these results to plenary requires a statistical “win” (usually two-sided). It appears criteria were met, implying a rigorous analysis that OS was statistically robust.

Nonetheless, observers will examine details: was OS tested in an intent-to-treat population? Did any imbalances or missing data affect outcomes? Summit’s filings and ASCO abstract likely detail the analysis plan. The broad 95% CI (0.50–0.87) shows some uncertainty. However the consistent PFS‐OS trend (HRs 0.60→0.66 from interim PFS to OS) and lack of survival curve crossover support a true benefit.

Comparison to Global Standards

Critics caution that Chinese trials often report longer survival due to patient differences. For example, Chinese NSCLC patients generally have lower exposure to subsequent lines of therapy (e.g. newer TKIs, targeted therapies, or later immunotherapies) than Western patients (^[35]). The control arm’s median OS of 23.7 months is far higher than Keynote-407’s chemo-alone 11.3 months (^[10]) and even higher than global PD-1 combos (KEYNOTE median 15.9 mo) (^[10]). This suggests Chinese patients are living longer on first-line therapy, perhaps because second-line options are limited (unlike in US/EU where many drugs are available). A leading financial analyst remarked: “China’s lung cancer patients’ later-line treatment access is markedly lower than in the West. This difference can amplify perceived first-line survival benefit” (^[39]).

Given that, an international oncologist commented that these “impressive” survival numbers may not fully translate outside China. Indeed, in the global Phase III HARMONi-3 (first-line squamous) and RATIONALE-307 (tislelizumab in squamous), OS outcomes have been less dramatic. RATIONALE-307’s final analysis showed tislelizumab+chemo HR for OS ~0.68 (not statistically significant) (^[37]), albeit trending favorably, with median OS 15–16 months (^[37]). Compared to 27.9 vs 23.7 here, that is a huge numerical gap. Thus, consensus experts urge caution.

Analysts from Leerink Partners and Evercore note that “an OS degradation from the Chinese to the global trial would make the combination less compelling” (^[6]). Summit’s own financial slides explicitly acknowledge the regional treatment differences. Actually, a recent 10-K described that Chinese follow-up is only ~19-20 months (so OS data are “not fully mature”), and that Chinese controls might overestimate relative gains (^[39]). In other words, Summit expects the global HARMONi-3 results (due Q4 2026 for OS) to confirm or calibrate this finding.

That said, Polaris reports: even if effect shrinks, any positive OS signal in this context would be notable. But stakeholders will undoubtedly compare “the East vs West” carefully.

Competition and Broader Class Context

Ivonescimab is not alone in the PD-1×VEGF field. Several bispecific programs are at various stages worldwide (^[23]). For example, BioNTech’s BNT327 (PD-1/VEGFR2) is in global Phase III trials (^[23]); Merck in-licensed a similar PD-1/VEGFR2 bispecific LM-299 (formerly by LoopGen) in Nov 2024 (^[23]). Other Chinese bispecifics, like Genor’s PD-1/VEGF antibody, are also in development. None, however, have published pivotal data. Until now, no PD-1/VEGF bispecific has regulatory approval in any market (^[21]).

Ivonescimab’s success effectively makes it the class leader. If FDA/EU approvals follow, it would set a precedent for bispecifics. Investors note that Pfizer, Merck, BMS, etc. will watch these results closely (^[11]) (^[19]). Some analysts predict that a positive result could accelerate trials of other PD-1/VEGF candidates (e.g. LM-299 might have FPI 2025) and trigger further partnerships. The fact that Akeso/Summit’s ivonescimab combined with chemo “essentially merged Keytruda and Avastin” into one molecule (^[11]) underscores its novelty. If ivonescimab becomes a global standard, it could reshape NSCLC paradigms and boost the broader field of dual-targeting immunotherapies.

However, the competitive landscape is intense. First-line NSCLC already has multiple PD-(L)1 combos approved (Keytruda, Tecentriq, etc), and emerging ADC (antibody-drug conjugate) therapies (like herniogen’s Enfortumab) are entering. Even in squamous NSCLC, Pfizer/Seagen’s T-DXd (trastuzumab-deruxtecan) is being explored. For PD-1/VEGF specifically, the relevance of OS benefit will be weighed: will oncologists adopt a new agent if survival is proven, or stick with existing broadly-effective regimens? Cost and safety comparisons (for example, grade-3 neutropenia was higher with ivonescimab) will factor in.

Expert Commentary

Oncology thought leaders have responded with cautious optimism. City of Hope’s Dr. Christine Lovly, a thoracic oncology expert, observed that “this cancer is particularly hard to treat, making new methods welcome,” noting that the results will spur interest in dual-targeting antibodies (^[19]). She also urged patience: “The data are intriguing, but still immature” (^[40]), highlighting the need to see long-term curves.

Analysts likewise see high stakes. Leerink’s Daina Graybosch quipped that some KOLs were so confident of a big OS lift (even >50%) that they had a friendly wager on it (^[41]). Graybosch herself warned that as a plenary presentation, the data will be “mined” by critics (^[42]) — e.g. scrutinizing crossover rates and subsequent therapies. An Evercore report cautioned that investors had been expecting an attenuated benefit outside China, so any surprise here was a boon but set a high bar for the global read-out (^[6]) (^[7]).

Industry media also marked the milestone. Fierce Pharma noted this as China’s “first-in-class PD-1/VEGF inhibitor” and emphasized the plenary honor and scrutiny (^[3]). The Straits Times highlighted that ivonescimab boosted survival by ~4 months and called the bispecific “a closely watched new class of treatments” (^[43]). It also underscored the worldwide investment rush: “Numerous drugmakers … have pledged billions to [PD-1/VEGF] bispecific antibodies (^[11]).”

Notably, Chinese financial press framed it as a national breakthrough and a “global heavyweight” debut (^[44]). A Chinese report lauded ivonescimab as a “milestone” and “symbolic” study in lung precision medicine (^[45]), while also outlining controversies: e.g. differences in patient populations, an unusually strong control arm in China, and a failed global Phase III (HARMONi-3) in interim PFS (^[46]). We will delve into these issues next.

Contextual Considerations and Uncertainties

Several caveats remain. First, generalizability: the HARMONi-6 enrollment was entirely Chinese, with no Western patients. Asians may respond differently, and background therapy is dissimilar. For example, the control median OS of 23.7 months far exceeds that seen in global trials of even PD-1 combos (often ~12–16 months) (^[10]). The high control survival suggests Chinese patients had limited access to later-line treatments, which can inflate apparent benefit. A Chinese financial analysis explicitly warned that the OS signal “may not be directly replicated in diverse global populations, posing a risk to its international adoption” (^[39]).

Moreover, the HARMONi-6 control arm (tislelizumab+chemo) outperformed global expectations: Keynote-407’s pembrolizumab+chemo had median OS ~15.9 months (^[10]), whereas the H6 control (tisle) reached 23.7 months in China. A noted concern is that if the control does remarkably well (perhaps due to local patient factors or chance), the relative HR benefit might be misleadingly large. Indeed, the Chinese article observed that the H6 control’s OS was much better than KEYNOTE’s K-drug data, implying that “the relative benefit of ivonescimab could be overestimated” (^[47]).

Another point: HARMONi-3 Global Trial. Summit’s own multi-regional Phase III HARMONi-3 trial in first-line NSCLC (with separate squamous and non-squamous cohorts) was notably failing its interim PFS in the squamous arm (reported April 2026) (^[48]). In that trial, ivonescimab+chemo did not meet the prespecified PFS endpoint in the planned interim (likely Singapore data). This raised questions about whether ivonescimab’s dramatic Chinese PFS effect would hold in a mixed population. Analysts point out that if the PFS does drop globally, the OS gain might shrink too (^[6]). Evercore commented that if the “deterioration isn’t as dramatic as previously thought, that could be the saving grace until H3 OS data” (^[7]). In short, Summit and investors will keenly watch the final HARMONi-3 OS: if it confirms benefit in Western patients, that will cement ivonescimab’s global prospects; if not, adoption may stall outside Asia.

Finally, safety and logistics: Ivonescimab requires intravenous infusion with chemo, similar to several existing regimens, so no new patient burden. Its safety (notably, higher hematologic toxicity) will require monitoring but did not raise fatal signals. Manufacturing scale-up may be an issue – Summit must ensure reliable supply (they are transferring tech and procuring fabs (^[49])). Fixing pricing (possibly premium, given its status as a novel bispecific) could also be tricky in cost-sensitive markets.

Overall, while HARMONi-6’s data are compelling, they arrive with many “ifs”: if the global follow-up replicates benefit, if regulators accept Chinese-led evidence, and if competing therapies don’t overtake the market by then. We turn next to the unique significance of this result – both scientifically and geopolitically – as China’s oncology research takes a leading role at ASCO.

Significance of the ASCO Plenary: China’s Rise in Oncology

Ivonescimab’s ASCO plenary berth was hghly notable. ASCO (an international U.S.-based oncology meeting) reserves its plenary sessions for only the most practice-changing, global-impact trials. On May 31, 2026, HARMONi-6 was one of only three plenary reports sat ASCO, joining breakthroughs in other cancers (^[50]). The fact that ivonescimab — a “China-originated” agent — earned this slot is historic. One Fierce Pharma report explicitly called it a “high-stakes plenary” and emphasized it was “the first China-developed asset to score this primetime slot in over six decades” (^[3]). Indeed, most drugs at ASCO plenary have been developed by Western (US/EU/Japanese) companies with global trials; a Chinese firm’s R&D effort is unprecedented to climb that high so early.

In Chinese media, the tone was patriotic and proud. Sina Finance’s front-page coverage in late May proclaimed it a “global record rewrite,” underscoring “the first China-original oncology drug on ASCO’s main stage” (^[44]). Chinese analysts framed this as a breakthrough marking “Chinese innovation stepping to the global frontier” (^[44]). Private biotech circles in China (e.g. antibody industry blogs) had hyped ivonescimab as a national victory. However, they also noted the “ultimate test” was coming, as “the world’s oncology community will subject this homegrown therapy to intense scrutiny and a final exam” (^[44]). Thus, the media reflected national pride mixed with caution – a sentiment echoed by U.S. experts like Dr. Lovly (“stigmatize success but we need longer data” (^[40])).

From a scientific standpoint, the plenary placement signals that the global research community regards ivonescimab’s data as potentially paradigm-shifting. As Fierce’s preview noted, if HARMONi-6 OS is positive, it would be “the first regimen to demonstrate a survival benefit over a PD-1/chemotherapy combination in first-line NSCLC in a phase 3 trial” (^[8]). That alone justified top billing. Among the ASCO audience, achieving a 34% hazard reduction in survival against a modern immunotherapy backbone is career-making. For a company like Summit (known previously only for neurological drug moratoriums), and Akeso, it instantly thrusts them into international spotlight.

Moreover, this legitimizes China’s role in cutting-edge oncology. Over the past decade, Chinese companies have increasingly entered global drug development (e.g. BeiGene’s antibody programs, Innovent’s PD-1), but few have claimed an outright “first” in trial results. Ivonescimab now joins a short list. It may pave the way for greater inclusion of non-Western patient data in global drug approval. As one commentary put it, the success “symbolizes China’s innovative drugs reaching the global frontier” (^[44]). Practically, it may encourage the FDA/EMA to consider approving drugs based on foreign trials, given quality data – especially if a Western bridging study is not possible.

For Summit and Akeso, the prestige of the plenary cannot be overstated. It essentially “forces” global attention on ivonescimab. Clinicians around the world will now ask: Should we be using this drug? Will NCCN guidelines incorporate it? Will FDA accept the Chinese-led data? Insurance payers will take note if FDA labels it. The hype raises Summit’s profile and (in the investor view) likely raises the bar on what is expected. The flip side is, by taking on the plenary spotlight, the trial will face “minced and scrutinized” analysis (^[42]). Any warts must now be openly defended.

Summit Therapeutics and Commercialization Outlook

Summit Therapeutics (Florida, Nasdaq: SMMT) is the exclusive licensee/developer of ivonescimab in most global markets (ex-China) (^[4]). Its entire strategic focus is on ivonescimab; no other product in its pipeline appears to have comparable weight. Summit’s challenge now is to transform trial success into revenue. We examine Summit’s progress and plans.

Licensing and Development Pipeline

As noted, Summit’s 2022 Akeso deal granted it rights to ivonescimab throughout North/South America, Europe, Japan, Mideast/Africa, and (as of June 2024) Latin America (^[4]). Summit paid ~$500M upfront (^[4]), and agreed to milestone payments for each drug approval, plus tiered royalty rates in the “low double digits” on net sales (^[14]). The agreement stipulates Summit controls development, commercialization, pricing, and reimbursement in these territories (^[14]). Thus Summit effectively owns ivonescimab in all major markets – but also bears the costs of development and commercialization.

Summit’s pipeline, as of its 2024 annual report, is tightly centered on ivonescimab: its documents list no other product candidates of significant maturity. Summit’s ongoing global trials are precisely:

• HARMONi (EGFR-mutant NSCLC), a Phase III with ivonescimab+chemo vs placebo+chemo in patients with EGFR mutations after TKI therapy (^[51]) (^[35]). Enrollment finished Q4 2024; in May 2025 they reported the primary PFS endpoint was met (HR=0.52) (^[51]). This formed the basis for Summit’s FDA BLA, accepted in Jan 2026 (^[5]) (PDUFA Nov 14, 2026). The submission covers the indication: EGFR-mutated, locally advanced or metastatic non-squamous NSCLC post-TKI. Summit estimates >14,000 U.S. patients/year fit this profile (^[5]) (a moderate niche).

• HARMONi-3 (Global NSCLC first-line), a Phase III comparator of ivonescimab+chemo vs placebo+chemo, with separate squamous and non-squamous cohorts (^[18]). Squamous results are expected first (primary endpoints PFS/OS per cohort), with interim PFS already performed Q2 2026 (^[52]). The squamous cohort’s final OS data is not due until 2H26 (possibly after the ASCO). The U.S. arm of HARMONi-3 is identical to the China trial (ivonescimab+chemo vs placebo in patients of any PD-L1 and histology, stratified).

• HARMONi-7 (Global monotherapy) – a Phase III in first-line PD-L1-high NSCLC (all histologies) with ivonescimab vs pembrolizumab monotherapy . This was initiated based on HARMONi-2’s promising PFS (HR=0.51 vs Keytruda) (^[16]). Summit activated U.S. sites for H7 in late 2024 (^[17]). If successful, this could allow single-agent ivonescimab for eligible patients.

Summit says it will “review Chinese trial data” as part of global development plans (^[53]). In practical terms, the positive HARMONi-6 results might inform Summit’s strategy: they could file for a new indication (squamous NSCLC) in the U.S. based on bridging data or launch a new trial if needed. However, regulatory authorities typically want local data or at least multinational trial evidence. Summit may therefore emphasize HARMONi-3 (which in the West is placebo-controlled) more for U.S. filing. Alternatively, Summit might lobby that H6 (with Tislelizumab) is a “non-inferiority” type control to Keytruda, making it acceptable evidence with an unconventionally strong control.

Regulatory Status and Approval Path

Summit’s immediate path is the pending BLA in EGFR-mutant NSCLC. The FDA accepted the BLA on Jan 29, 2026, for this second-line post-TKI indication (^[5]). The PDUFA target date is 14 November 2026 (^[5]). Approval would make ivonescimab + chemo the first approved PD-1/VEGF bispecific in the U.S. It would fill a niche for EGFR-mutant patients who have exhausted standard TKIs and are not candidates for effective targeted therapy. Summit has emphasized that no FDA-approved regimen has shown an OS benefit in that post-TKI setting (^[54]), suggesting ivonescimab could potentially claim that advantage.

For first-line NSCLC (both squamous and non-squamous), Summit has no immediate filing. If US HARMONi-3 confirms PFS/OS benefit, Summit could file for first-line approval (or a supplement to the EGFR NDA). If HARMONi-3 fails, Summit might focus solely on the second-line niche (less competitive, hence safer). The ASCO squamous data, being versus a non-FDA PD-1 (tisle), may not by itself satisfy regulators. However, it will bolster Summit’s narrative of strong efficacy.

Beyond FDA, Summit’s license covers Europe and other regions. EMA will likely require similar evidence; Summit has indicated that after FDA, they plan submissions in EU, Japan, etc. CME India, Korea, etc. may follow, possibly using local data. Summit’s license gives them Western rights; Akeso can pursue ivonescimab’s China/NMPA filings independently (and indeed ivonescimab was approved in China as monotherapy for EGFR-mutant NSCLC in 2025 (^[55])). But Summit will want approvals in its own markets first.

Commercialization Strategy and Market Potential

If approved in late 2026, ivonescimab would likely launch in 2027 for EGFR-NSCLC. Summit signals it is preparing: its June 2025 corporate presentation (JPM 2025) highlighted “high speed execution” and building sales infrastructure (^[56]). We anticipate Summit will recruit a specialized oncology sales force (possibly expanding from Boston to more markets) to target thoracic oncologists and academic centers. They will need to educate physicians on the bispecific’s profile and how it compares to existing regimens.

Pricing will be delicate. Consider Keytruda in squamous: cost ~ $150K/year in the U.S. Ivonescimab + chemo (dosing every 3 weeks for 1-2 years) might command a premium as a novel mechanism, but payers may resist if multiple new agents exist. Summit’s license gives them pricing control (^[14]), but they will face health technology assessments. Likely, ivonescimab will launch as an option among several, so Summit may initially position it where it has clear evidence of superiority (e.g. to be “preferred” over standard PD-1 combos for specific patient subsets). Over time, if additional trials (HARMONi-7, HARMONi-3) succeed, they could expand label and drive more uptake.

What is the U.S. addressable market? For EGFR-mutant patients in second-line, Summit states >14,000/year (^[5]). That is roughly the population: ~13% of NSCLC (EGFR-mutant prevalence) of ~220,000 NSCLC cases, times fraction eligible for chemo = on the order of 10-15k. If ivonescimab grabs a significant share, even at $100K/patient, revenue could approach $1–2B in that niche alone. If Summit succeeds in bringing ivonescimab earlier (first-line squamous or monotherapy in PD-L1-high), the market could jump to mainstream NSCLC (a far larger patient base, on the order of 100k+ yearly). Even if it captures a minority of that (say 10%), ivonescimab could become a blockbuster. Currently, Keytruda plus chemo’s share in squamous is well over 50%, so there is room if survival advantage is proven.

Competition risk is real. By late 2027, other PD-1/VEGF bispecifics may be vying for approval, including Pfizer’s or Merck’s (though none has OS data yet). Also, combination treatments (e.g. PD-1 + Lenvatinib (LENVIMA) by Eisai or others) may seek expansion. Summit will have to highlight that ivonescimab’s single-agent efficacy in OS sets it apart, as opposed to adding separate VEGF inhibitors, which can have higher toxicity. If the FDA requires an advisory committee (likely given novelty), Summit’s leaders will present these Phase III data, seeking endorsement.

In their SEC filings, Summit acknowledges key commercialization risks: manufacturing must scale up (initial drug substance supply was licensed from Akeso, but Summit must secure a second source) (^[49]). They also note dependency on the Akeso alliance and on regulatory approvals (failure could delay commercialization) (^[57]). The $15M amendment payment for territory expansion shows Summit’s commitment to global reach, yet now they need to recoup that investment via sales.

Analyst and Investor Reaction

Summit’s stock and investor sentiment have been volatile around featured data. Post-Lancet 2025, Summit shares had spiked, then dipped after the global HARMONi-3 PFS miss in Apr 2026 (^[58]). ASCO 2026 may trigger another rally: companies with positive phase III lung cancer data often see big capital inflows. On the call, analysts from Citi, Evercore and others will quiz Summit management on commercialization timelines, patient market sizing, and anticipated pricing/reimbursement. They will also ask: “Will Summit itself file for squamous indication internationally, or defer to Akeso?” (Likely Summit, since tislelizumab isn’t approved in the West).

Ultimately, Summit’s valuation will depend on their ability to execute. If ivonescimab is approved in 2026, Summit must ramp up commercial efforts quickly in 2027. They will need partnerships with distributors, MSL teams, etc. It might even make Summit an M&A target: a mid-sized pharma might buy Summit to gain ivonescimab commercial rights. For now, all eyes are on the data, FDA’s November 2026 decision, and the follow-up global trial results.

Commercialization Table

Below is a summary of key license and regulatory milestones relevant to Summit’s commercialization:

This table highlights the path from licensing to launch. With the BLA accepted for a November 2026 FDA decision, Summit is on track for a 2027 U.S. launch in its EGFR-mutant indication. Future regulatory filings (e.g. U.S. NDA for squamous NSCLC) will depend on forthcoming trial readouts. In Europe and other regions, Summit will likely align filings to FDA timelines but may face additional data requirements (some agencies prefer local bridging trials). Summit’s commercialization outlook thus hinges on timely approvals and successful introduction into a specialized NSCLC market, with potential for expansion pending further evidence.

Case Study: Ivonescimab vs Pembrolizumab (HARMONi-2)

To illustrate the broader promise of PD-1/VEGF therapy, consider the HARMONi-2 trial (Lancet 2025). This smaller Chinese Phase III compared ivonescimab monotherapy against pembrolizumab in advanced PD-L1-positive NSCLC (any histology). At a planned interim, median PFS was 11.1 vs 5.8 months favoring ivonescimab (HR=0.51, 95% CI 0.38–0.69) (^[16]) – a 49% risk reduction. One-sided p<0.0001 confirmed statistical significance. Although OS data were not yet mature, these PFS results were dramatic enough to earn a Lancet publication soon after KEYNOTE-042 (Pembrolizumab vs chemo) and ahead of the U.S. KEYNOTE-024 5-year readout.

This HARMONi-2 result shows ivonescimab’s potent single-agent activity: it essentially “doubled” Keytruda’s PFS in PD-L1-positive tumors (^[16]). Expert commentators interpreted it as proof-of-concept that dual blockade is synergistic. In fact, Summit cited H2 data to justify launching H7 globally. Nevertheless, HARMONi-2’s comparator (single-agent pembrolizumab) is not identical to standard-of-care in most markets (where PD-1 monotherapy is reserved for high PD-L1, and given with chemo for others). Still, the magnitude (HR=0.51) was the largest PFS gap seen in any first-line NSCLC comparison. Summaries noted “the PFS benefit was broadly consistent across PD-L1 subgroups” (^[16]), implying even intermediate PD-L1 patients gained.

Ivonescimab’s toxicity in HARMONi-2 was slightly higher than Keytruda: Grade≥3 events occurred in 29% vs 16% (^[16]). This highlighted that the bispecific might carry more toxicity, likely from its VEGF component (more cytopenias). Still, the manageable profile and strong efficacy convinced many that ivonescimab could be superior for PD-L1-high patients with squamous histology too – spurring the focus on H6.

Thus, HARMONi-2 is a real-world example of “beating pembrolizumab” in NSCLC (^[60]). While that phrase in headlines was a bit shorthand (it beat it in PFS, not yet OS), the 0.51 HR is often cited in investor decks. It demonstrates the potential ceiling of ivonescimab’s performance against the PD-1 standard. For context, KEYNOTE-024 (non-sq, PD-L1≥50%) had a pembrolizumab vs chemo PFS HR=0.60 (^[16]); ivonescimab’s HR=0.51 in H2 suggests a much stronger effect. Whether OS will ultimately mirror that advantage remains to be seen.

Implications and Future Directions

The HARMONi-6 data portend several implications:

• New Frontline Option: If regulators accept these results, ivonescimab+chemo could become a new frontline standard in squamous NSCLC, at least in some markets. It could challenge existing PD-1 combinations (Keytruda or Tecentriq plus chemo) by offering deeper and more durable responses. Clinical guidelines (e.g. NCCN) would likely list it as a category 1 or 2A option for squamous. Oncologists may choose it particularly for patients predicted to do poorly on PD-1 alone (e.g. PD-L1-low).

• Biomarker Development: The apparently PD-L1–agnostic benefit might shift thinking about biomarkers. Trials might look at VEGF or other angiogenesis markers for predicting responses to bispecifics. Researchers will retrospectively analyze HARMONi-6 to find signatures of exceptional responders.

• Combination Strategies: The success of a PD-1/VEGF bispecific may spur trials combining ivonescimab with other agents. For example, adding it to EGFR inhibitors in EGFR-mutant NSCLC, or to other novel therapies in squamous (like antibody-drug conjugates). Conversely, we may see trials of anti-VEGF/TKI + PD-1, but eventually the bispecific format may be favored.

• Global Regulatory Precedent: Summit’s interactions with FDA/EMA will be closely watched as a case study: Can positive data from predominantly Chinese patients (and using a Chinese control drug) support approval in the West? Success could open doors for other multinational late-stage trials conducted in Asia to count overseas. If the FDA convenes an advisory committee, it will implicitly address this question.

• Chinese Drug Ecosystem: Ivonescimab’s headline feat might encourage more cross-border partnerships. Smaller Chinese biotech companies may be emboldened to seek ASCO presentations for their late-stage data, or to partner early with U.S. firms (as Akeso did). It also highlights the importance of Chinese clinical trial capacity: large patient flows there enabled swift Phase III completion. The model of a Chinese-origin drug achieving global recognition could repeat (e.g. HengRui’s anlotinib in other indications, or CStone’s PKI in combination therapies).

• Market Response: Payers’ decisions will be key. In China, Akeso itself may seek local approvals for ivonescimab for squamous NSCLC (pending NMPA confidence). In the U.S./EU, Summit will price access. Since ivonescimab is novel, it may justify high pricing if it indeed improves survival (cost-effectiveness analyses will consider life-months gained). If other bispecifics emerge, a pricing “race” could ensue, which might limit margins.

• Scientific Investigations: The HARMONi-6 results will likely generate numerous academic discussions. Why did the VEGF component not increase bleeding in squamous? (It hints that the bispecific’s partial VEGF blockade may be gentler than full-dose bevacizumab.) Could this approach apply to other squamous cancers (head & neck, esophageal)? Will the immune milieu of squamous lung be particularly susceptible to angiogenic synergy? Translational studies from trial biopsies may follow.

• Long-term Outcomes: Ultimately, the critical questions are: how long do responding patients remain alive, and how many long-term survivors (5-year)? The ASCO data are interim; full analysis including mature OS, quality of life, and cumulative AEs will come. If ivonescimab yields even a small tail of survivors beyond 5 years, that would be revolutionary for “incurable” lung cancer. Oncologists will await final survival curves publicly (potentially in New England Journal of Medicine or Lancet, given the importance).

Conclusion

The HARMONi-6 ASCO 2026 plenary highlights a potentially paradigm-shifting advance in lung cancer therapy: ivonescimab, a PD-1×VEGF bispecific, significantly outperformed a PD-1 standard-of-care in first-line squamous NSCLC (^[1]) (^[2]). This is an extraordinary moment — the first time a China-origin cancer drug led such a global conference session (^[3]). The trial showed deep progression-free survival gains (HR=0.60) and, critically, a robust overall survival benefit (HR=0.66) for ivonescimab+chemo (^[1]) (^[2]). The findings were consistent across PD-L1 levels (^[31]), suggesting broad applicability.

From a clinical research perspective, HARMONi-6 provides proof that dual PD-1/VEGF targeting can produce more durable remissions than PD-1 blockade alone or in combination with chemotherapy. It validates the bispecific strategy and will spur further innovation and trials in this class. For Chinese biotech, this marks a coming-of-age, demonstrating that a domestic R&D program (Akeso) can deliver world-class data on an international stage. It may encourage greater East-West collaboration and regulatory flexibility for future drugs.

For Summit Therapeutics, the immediate takeaway is that its gamble has paid off: ivonescimab now has blue-chip data. Summit must now execute: secure FDA approval for the EGFR indication, and plan for broader launches. The market potential is large, but Summit faces challenges in production, pricing, and confirming global efficacy. How ivonescimab is positioned against entrenched PD-1 therapies will determine its commercial success.

Importantly, skeptics remain: Will these results hold in non-Chinese populations? Will the toxicity be acceptable long term? Global Phase III trials still need conclusive data. If the OS benefit endures and can be repeated, ivonescimab will be a landmark for patients — offering a new option that measurably extends life in a battle with traditionally poor outcomes. Conversely, if further data temper the early exuberance, it will still stand as a bold step forward for combination immunotherapy.

In any case, the HARMONi-6 results and ivonescimab’s story have profound future implications. They herald a new generation of cancer drugs, more internationalized drug development, and a resurgent Chinese presence in oncology. The outcomes of upcoming regulatory decisions (FDA PDUFA Q4 2026) and ongoing global trials (HARMONi-3, HARMONi-7) will shape the next chapters. For now, the oncology community will glean every possible lesson from ivonescimab’s success — a watershed moment arrived that will influence treatment standards and inspire more research on PD-1/VEGF bispecifics.

This report has charted the journey: from trial design and data («data analysis»), through real-world context and expert opinion («case studies»), to market strategy and future considerations. The evidence is robust: ivonescimab has demonstrated significant survival gains (^[1]) (^[2]). Whether it delivers on its promise in the global arena remains to be confirmed. But for now, the momentum is unmistakable, and stakeholders in biotech, oncology, and healthcare policy will need to carefully navigate the opportunities and questions it has opened.

References

• Paz-Ares L et al. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer. NEJM 2018;378:2268–2281. (KEYNOTE-407) (^[9]) (^[10]).
• W. Zhiwei Chen et al. Ivonescimab plus chemo vs Tislelizumab plus chemo, first-line advanced squamous NSCLC (HARMONi-6): Lancet 2025, DOI:10.1016/S0140-6736(25)01848-3. (^[2])
• “Overall Survival Benefit with Ivonescimab Plus Chemo in Advanced Squamous NSCLC.” The ASCO Post, June 1 2026 (report on ASCO 2026) (^[1]) (^[31]).
• Stenger M. “First-Line Ivonescimab or Tislelizumab Plus Chemo in Advanced Squamous NSCLC.” The ASCO Post, Nov 6 2025 (HARMONi-6 interim) (^[2]) (^[61]).
• Liu A. “Summit shares details of ivonescimab's first global phase 3 trial.” Fierce Pharma, May 30 2025 (HARMONi topline) (^[62]).
• Liu A. “Summit shares tumble on interim PD-1/VEGF trial miss.” Fierce Pharma, Apr 30 2026 (HARMONi-3 info, Summit analysis) (^[48]) (^[22]).
• Liu A. “ASCO preview: Expectations jacked up, Akeso’s ivonescimab to face scrutiny…” Fierce Pharma, May 27 2026 (pre-ASCO) (^[3]) (^[8]).
• Goodman A. “Atezolizumab Plus Chemo Extends Survival in Squamous NSCLC.” The ASCO Post, July 25 2018 (IMpower131) (^[10]).
• Dhillon S. “Ivonescimab: First Approval.” Drugs 2024 Sep;84(9):1135–1142 (review of ivonescimab) (^[63]).
• Summit Therapeutics Inc. SEC 10-K 2025 (filed Feb 2026) – sections on pipeline and license (^[18]) (^[17]); also license details (^[4]) (^[14]).
• Summit Therapeutics Inc. Press Release, Jan 29 2026 (SEC filing): “FDA Accepts BLA for Ivonescimab…EGFRm NSCLC.” (^[5]).
• Summit Therapeutics SEC Form S-3/A 2024 (filed Jan 2025) – license agreement summarized (^[4]) (^[14]).
• Summit Therapeutics press images: JPM 2025 slides (via SEC) (^[64]) showing PDUFA date and population.
• Straits Times, “Lung cancer patients on drug from China’s Akeso lived longer.” May 31, 2026 (^[43]) (^[65]).
• Sina Finance (Antibody News) “China’s first oncology drug debuts at ASCO Plenary” May 28, 2026 (^[44]) (^[46]).
• Lovly C (City of Hope). Quoted in ASCO 2026 press coverage (^[19]) (^[40]).
• Citi Research note (2026), Evercore note (2026): reported in feeds, cited in Fierce Pharma (^[58]) (^[7]).
• Rationale-307 final analysis. Ann Oncol 2024;29:280–290. (Tislelizumab + chemo vs chemo) (^[37]) (^[36]).
• Selected ASCO abstracts: HARMONi-6 LBA4 (2026) (^[1]), HARMONi-3 updates.

(References are numbered by source ID and line numbers as [ID†Lx-Ly].)